Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo.

NCT01569113 is registered in ClinicalTrials.gov with HRA Pharma as lead sponsor.

NCT NCT01569113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01569113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo.
Lead sponsor
HRA Pharma
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2012
Completion date
August 31, 2012
Enrollment
76 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

emergency contraception